Direvo and Danisco Collaboration Yields New Industrial Enzyme
DIREVO Biotech AG announced that an industrial enzyme protein engineering project in collaboration with Danisco A/S, has yielded a significantly improved phytase enzyme. The project exploited Direvo's high throughput, robotic screening and directed evolution technologies for enzyme optimization.
Phytic acid is the main phosphate storage molecule in plants. Phytase enzymes release phosphate from phytic acid and thus have applications in multiple industrial markets.
"This is the first enzyme derived from Direvo's technology platform to reach the market, and we are extremely proud to see this further validation of our approach", said Anindya Mukherjee, Executive VP Industrial Biotechnology of Direvo. "The collaboration with Danisco A/S and its Genencor Division has been a great success to date and we look forward to many similar successes in future collaborations".
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Thermo Fisher Scientific and Samsung Electronics to Collaborate on Point-of-Care Diagnostic Solutions
DeCODE Study Links Gene Variant to Risk of Breast Cancer
U.S. Food and Drug Administration (FDA) Approves Recombinant Protein Treatment for Tibia Fractures - Wyeth's rhBMP-2/ACS Offers Potential for Improved Fracture Healing

FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant - "These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"
New fat graft procedure promises long-term results in breast reconstruction
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients
Sygnature Discovery: New Bioscience Group Fully-Operational & Winning Projects
Arkansas_Department_of_Human_Services_v._Ahlborn

New active substance against parasites
Biovitrum and Syntonix begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for treatment of Hemophilia B

Intra-Automation GmbH - Grevenbroich, Germany
